A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset

Trial Profile

A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs DP b99 (Primary)
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms MASCI
  • Most Recent Events

    • 14 Feb 2013 New trial record
    • 07 Feb 2013 Primary endpoint 'Rankin-scale' has not been met.
    • 07 Feb 2013 Results presented at the 38th International Stroke Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top